Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

134 ARTÍCULOS , VIENDO DEL 61 AL 75

APOE-related biomarker profiles in non-pathological aging and early phases of Alzheimer's disease

Reinvang I, Espeseth T, Westlye LT.

Neurosci Biobehav Rev. 2013 Sep;37(8):1322-35. doi: 10.1016/j.neubiorev.2013.05.006. Epub 2013 May 20.

Cerebrospinal fluid biomarkers of Alzheimer's disease in healthy elderly

Randall C, Mosconi L, de Leon M, Glodzik L.

Front Biosci (Landmark Ed). 2013 Jun 1;18(3):1150-73. doi: 10.2741/4170.

Ushering in the study and treatment of preclinical Alzheimer disease

Langbaum JB, Fleisher AS, Chen K, Ayutyanont N, Lopera F, Quiroz YT, Caselli RJ, Tariot PN, Reiman EM.

Nat Rev Neurol. 2013 Jul;9(7):371-81. doi: 10.1038/nrneurol.2013.107. Epub 2013 Jun 11.

Inflammatory proteins in plasma are associated with severity of Alzheimer's disease

Leung R, Proitsi P, Simmons A, Lunnon K, Güntert A, Kronenberg D, Pritchard M, Tsolaki M, Mecocci P, Kloszewska I, Vellas B, Soininen H, Wahlund LO, Lovestone S.

PLoS One. 2013 Jun 10;8(6):e64971. doi: 10.1371/journal.pone.0064971. Print 2013.

Dissociable effects of Alzheimer disease and white matter hyperintensities on brain metabolism

Haight TJ, Landau SM, Carmichael O, Schwarz C, DeCarli C, Jagust WJ; Alzheimer's Disease Neuroimaging Initiative.

JAMA Neurol. 2013 Aug;70(8):1039-45. doi: 10.1001/jamaneurol.2013.1878.

Diffusion tensor imaging measures of normal appearing white matter in patients who are aging, or have amnestic mild cognitive impairment, or Alzheimer's disease

Wang JH, Lv PY, Wang HB, Li ZL, Li N, Sun ZY, Zhao BH, Huang Y.

J Clin Neurosci. 2013 Aug;20(8):1089-94. doi: 10.1016/j.jocn.2012.09.025. Epub 2013 Jun 17.

Evaluating amyloid-β oligomers in cerebrospinal fluid as a biomarker for Alzheimer's disease

Hölttä M, Hansson O, Andreasson U, Hertze J, Minthon L, Nägga K, Andreasen N, Zetterberg H, Blennow K.

PLoS One. 2013 Jun 14;8(6):e66381. doi: 10.1371/journal.pone.0066381. Print 2013.

Fluid biomarkers in Alzheimer's disease - current concepts

Rosén C, Hansson O, Blennow K, Zetterberg H.

Mol Neurodegener. 2013 Jun 21;8:20. doi: 10.1186/1750-1326-8-20.

2013 Alzheimer Award

J Alzheimers Dis. 2013;36(3):413-4. doi: 10.3233/JAD-139903.

Is there a causal link between inflammation and dementia?

Enciu AM, Popescu BO.

Biomed Res Int. 2013;2013:316495. doi: 10.1155/2013/316495. Epub 2013 Jun 6.

Decoding Alzheimer's disease from perturbed cerebral glucose metabolism: implications for diagnostic and therapeutic strategies

Chen Z, Zhong C.

Prog Neurobiol. 2013 Sep;108:21-43. doi: 10.1016/j.pneurobio.2013.06.004. Epub 2013 Jul 11.

Elevated levels of multiple biomarkers of Alzheimer's disease in the aqueous humor of eyes with open-angle glaucoma

Inoue T, Kawaji T, Tanihara H.

Invest Ophthalmol Vis Sci. 2013 Aug 9;54(8):5353-8. doi: 10.1167/iovs.13-12245.

Oxidative stress in blood in Alzheimer's disease and mild cognitive impairment: a meta-analysis

Schrag M, Mueller C, Zabel M, Crofton A, Kirsch WM, Ghribi O, Squitti R, Perry G.

Neurobiol Dis. 2013 Nov;59:100-10. doi: 10.1016/j.nbd.2013.07.005. Epub 2013 Jul 15.

Alzheimer's disease treated patients showed different patterns for oxidative stress and inflammation markers

Gubandru M, Margina D, Tsitsimpikou C, Goutzourelas N, Tsarouhas K, Ilie M, Tsatsakis AM, Kouretas D.

Food Chem Toxicol. 2013 Nov;61:209-14. doi: 10.1016/j.fct.2013.07.013. Epub 2013 Jul 16.

A phase 3 trial of semagacestat for treatment of Alzheimer's disease

Doody RS, Raman R, Farlow M, Iwatsubo T, Vellas B, Joffe S, Kieburtz K, He F, Sun X, Thomas RG, Aisen PS; Alzheimer's Disease Cooperative Study Steering Committee; Siemers E, Sethuraman G, Mohs R; Semagacestat Study Group.

N Engl J Med. 2013 Jul 25;369(4):341-50. doi: 10.1056/NEJMoa1210951.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias